SRT2104 (GSK2245840) SRT2104 Target Sirt1 Mitigates Macrophage Inflammation in Gout
Copy code to add this image to your page
Gouty arthritis is driven by acute inflammatory responses to monosodium urate (MSU) crystal deposition in synovial joints. Pathogenic progression relies heavily on resident and infiltrating monocyte-derived macrophages. Upon exposure to MSU microcrystals, macrophages undergo metabolic reprogramming and polarize toward a pro-inflammatory M1 phenotype. This phenotypic shift triggers the synthesis and release of potent inflammatory mediators, creating a self-amplifying cascade of tissue destruction and severe pain. Sirtuin 1 (Sirt1) operates as an NAD+-dependent class III deacetylase targeting non-histone regulatory proteins and transcription factors. In immune cells, Sirt1 modulates inflammatory gene expression by regulating transcriptional complexes and upstream kinase cascades. Small-molecule Sirt1 activators have consequently emerged as specialized tools to dissect Sirt1-mediated deacetylase activity in hyper-inflammatory cellular environments. In vitro model systems employing human THP-1 macrophages stimulated with lipopolysaccharide (LPS) alongside MSU crystals reproduce the primary pathological signals of acute gouty inflammation. Under these double-stimulated in vitro conditions, THP-1 macrophages exhibit robust upregulation of inflammatory enzymes and high-volume secretion of pro-inflammatory cytokines. Application of the selective Sirt1 agonist SRT2104 (GSK2245840) demonstrated pronounced anti-inflammatory activity. Treatment significantly diminished the secretion of primary inflammatory cytokines, including interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). Furthermore, levels of downstream lipid and gaseous inflammatory mediators—specifically prostaglandin E2 (PGE2) and nitric oxide (NO)—were markedly depressed. Monocyte chemoattractant protein-1 (MCP-1) secretion also decreased substantially in a dose-dependent manner. At the protein expression level, SRT2104 suppressed the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Both enzymes serve as hallmark markers for M1 macrophage polarization. Western blot analyses confirmed that Sirt1 activation directly impaired the phosphorylation kinetics of key mitogen-activated protein kinase (MAPK) nodes. Specifically, p38 MAPK and c-Jun N-terminal kinase (JNK) phosphorylation levels were significantly lowered following treatment. Attenuation of p38 and JNK activity interrupted downstream transcriptional execution. Nuclear factor kappa B (NF-κB) p65 subunit nuclear translocation was restricted, accompanied by a parallel suppression of activator protein-1 (AP-1) DNA-binding capacity. Because NF-κB p65 and AP-1 act as essential transcriptional drivers for iNOS, COX-2, and inflammatory cytokines, their concurrent inhibition disrupted the core transcriptional network driving M1 macrophage activation. Beyond inhibiting inflammatory kinase cascades, Sirt1 activation upregulated the Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) antioxidant pathway. Treatment induced nuclear accumulation of Nrf2, leading to elevated expression of Heme Oxygenase-1 (HO-1). This activation of the Nrf2/HO-1 axis restored redox homeostasis in stimulated THP-1 cells, causing a measurable decline in intracellular reactive oxygen species (ROS) levels. Elevated ROS normally functions as a secondary messenger that reinforces NF-κB and MAPK activation; thus, ROS neutralization further stabilized the non-inflammatory macrophage state. In summary, empirical evaluation in THP-1 macrophages indicates that Sirt1 activation effectively mitigates MSU crystal-induced inflammation and oxidative stress. By dual-targeting the p38/JNK/NF-κB/AP-1 and Nrf2/HO-1 pathways, the small molecule establishes a balanced regulatory landscape that suppresses M1 polarization. While these cell-based findings clarify the underlying molecular mechanisms, translational validation across in vivo animal models of gouty arthritis will be required to confirm target residence time and therapeutic windows.
Pharmacological Evaluation of Sirt1 Modulation in Macrophage Polarization
Copy code to add this image to your page
SRT2104 (GSK2245840) acts as a small-molecule Sirt1 activator that suppresses macrophage-mediated inflammatory responses in gouty arthritis. Upon binding Sirt1, the compound attenuates p38 and JNK MAPK phosphorylation, preventing downstream activation of NF-κB p65 and AP-1 transcription factors. Simultaneously, Sirt1 activation stimulates the Nrf2/HO-1 antioxidant axis, enhancing ROS scavenging capabilities. In THP-1 macrophages exposed to LPS and monosodium urate crystals, this dual pathway modulation inhibits COX-2 and iNOS expression, blocking the secretion of pro-inflammatory cytokines IL-1β, IL-6, TNF-α, PGE2, and NO.
Inhibition of MAPK and NF-kB AP-1 Phosphorylation Cascades
In MSU crystal-stimulated THP-1 macrophages, MAPK pathway activation drives inflammatory gene expression. SRT2104 suppressed p38 and JNK phosphorylation within hours of administration. Consequently, nuclear translocation of NF-κB p65 was reduced. The selectivity margin remained intact at effective assay concentrations. AP-1 DNA-binding activity decreased in parallel—a direct outcome of JNK signal blockade. This dual transcriptional suppression lowered COX-2 and iNOS protein levels. Cytokine secretion dropped markedly across all tested assays. Interleukin-1β release fell to near-baseline levels. Prostaglandin E2 synthesis ceased rapidly. These in vitro observations indicate that target engagement effectively interrupts early inflammatory signaling cascades.
Nrf2 HO-1 Antioxidant Axis Activation and ROS Clearance
Oxidative stress exacerbates crystal-induced cell damage. Nuclear translocation of Nrf2 occurred rapidly following treatment. Heme Oxygenase-1 protein expression rose significantly within the intracellular environment. Intracellular ROS generation dropped sharply as HO-1 accumulated. Elevated antioxidant capacity protected macrophages from secondary inflammatory activation. Under tested assay conditions, the compound prevented ROS-driven positive feedback to p38 MAPK. Cellular viability remained high throughout the treatment window. The restored redox state directly correlated with reduced M1 marker expression. Overall, activating Sirt1 coordinates an effective shift from inflammatory signaling toward cellular redox stability.